Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | SPHK2 | Q9NRA0 | 8/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.31 |
| ▸ | PRCP | P42785 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17865676 | 0.77 | BDKRB2 (0.36) | — | |
| SCHEMBL17865657 | 0.73 | HRH4 (0.40) | TDO2RIPK1HRH4 | |
| SCHEMBL17865712 | 0.72 | SPHK2 (0.30) | SPHK2SPHK1 | |
| SCHEMBL16525679 | 0.70 | TDO2 (0.36) | TDO2CA1CA2CA3CA6 | |
| SCHEMBL17865542 | 0.70 | HRH4 (0.54) | HRH4 | |
| SCHEMBL17865525 | 0.69 | F7 (0.41) | CA1CA2CA3CA6CA7 | |
| SCHEMBL16525685 | 0.69 | TDO2 (0.35) | TDO2CA1CA2CA3CA6 | |
| SCHEMBL16525680 | 0.68 | TDO2 (0.33) | TDO2CA1CA2CA3CA6 | |
| SCHEMBL17865642 | 0.68 | TDO2 (0.33) | TDO2CA1CA2CA3CA6 | |
| SCHEMBL17865543 | 0.67 | HRH4 (0.54) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160200709-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2016-07-14 | — | — | US | claimed |
| EP-3037418-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG Life Sciences Ltd. (KR) | 2016-06-29 | — | — | EP | claimed |
| US-10927097-B2 | Indole compound as inhibitor of necrosis | LG CHEM, LTD. (KR) | 2021-02-23 | — | — | US | disclosed |
| US-20160200709-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG LIFE SCIENCES LTD. (KR) | 2016-07-14 | — | — | US | disclosed |
| EP-3037418-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | LG Life Sciences Ltd. (KR) | 2016-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927097-B2 | Indole compound as inhibitor of necrosis | IDO1, IDO2, TNF | TDO2 19/4885CA1 1042/4885CA2 859/4885 |
| US-20160200709-A1 | INDOLE COMPOUND AS INHIBITOR OF NECROSIS | IDO1, IDO2, TNF | TDO2 17/4885CA1 1025/4885CA2 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.